Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZYXI 
Zynex Inc (ZYXI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZYXI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.85
1 Year Target Price $2.85
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.05M USD | Price to earnings Ratio - | 1Y Target Price 2.85 |
Price to earnings Ratio - | 1Y Target Price 2.85 | ||
Volume (30-day avg) 3 | Beta 0.92 | 52 Weeks Range 1.23 - 9.42 | Updated Date 08/15/2025 |
52 Weeks Range 1.23 - 9.42 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-23 | When Before Market | Estimate -0.12 | Actual -0.6513 |
Profitability
Profit Margin -19.79% | Operating Margin (TTM) -46.13% |
Management Effectiveness
Return on Assets (TTM) -12.11% | Return on Equity (TTM) -168.22% |
Valuation
Trailing PE - | Forward PE 16.61 | Enterprise Value 103089932 | Price to Sales(TTM) 0.32 |
Enterprise Value 103089932 | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 0.71 | Enterprise Value to EBITDA 20.66 | Shares Outstanding 30297400 | Shares Floating 15700437 |
Shares Outstanding 30297400 | Shares Floating 15700437 | ||
Percent Insiders 48.31 | Percent Institutions 18.52 |
Upturn AI SWOT
Zynex Inc
Company Overview
History and Background
Zynex, Inc. was founded in 1996. It is a medical technology company specializing in the design, manufacture, and marketing of non-invasive medical devices for pain management, rehabilitation, and neurological monitoring. The company has grown through product development and strategic acquisitions.
Core Business Areas
- Pain Management: Zynex's core business is focused on electrotherapy devices used for pain management, primarily focusing on reducing or eliminating the need for opioid pain medications.
- Rehabilitation: Offers devices to assist patients in rehabilitation settings.
- Neurological Monitoring: Development and sale of neurological monitoring systems.
Leadership and Structure
Thomas Sandgaard is the Chairman, President, and CEO. The company operates with a functional organizational structure, with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- NeuroMove: A neurological rehabilitation system designed to help stroke patients regain movement. Market share data is difficult to pinpoint precisely, but it competes with other neuro-rehabilitation devices. Competitors include companies that provide robotics and virtual reality-based rehab solutions.
- Evol Nutrition: A nutritional supplement line marketed towards Zynex patients and athletes. Revenue data not readily available. Competitors include major supplement brands like Glanbia (Optimum Nutrition) and Herbalife.
- NexWave: A device designed to reduce pain. Competitors include other electrotherapy devices, as well as pharmacological pain relief methods.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, stringent regulatory oversight, and increasing demand due to an aging population and rising healthcare costs. The electrotherapy and pain management segments are highly competitive.
Positioning
Zynex positions itself as a provider of non-invasive, drug-free pain management solutions. Its competitive advantage lies in its integrated business model encompassing device design, manufacturing, and direct sales.
Total Addressable Market (TAM)
The TAM for pain management and rehabilitation devices is estimated to be in the billions of dollars. Zynex's positioning focuses on capturing a share within the non-opioid pain management market, with focus on electrotherapy and related products.
Upturn SWOT Analysis
Strengths
- Vertically integrated business model
- Focus on non-opioid pain management solutions
- Direct sales force
- Strong relationships with physicians
Weaknesses
- Reliance on single product line
- High sales and marketing expenses
- Litigation Risks
- High dependence on reimbursements from healthcare providers
Opportunities
- Expansion into new markets (e.g., international)
- Development of new products and technologies
- Partnerships with healthcare providers and insurers
- Increased awareness of opioid crisis and demand for alternatives
Threats
- Increased competition from established medical device companies
- Changes in reimbursement policies
- Product liability claims
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- BONE
- ABI
- ALGN
- INMD
Competitive Landscape
Zynex competes with larger, more established medical device companies. Its competitive advantage lies in its focus on non-opioid pain management and its direct sales model. Disadvantages could include lower R&D budgets compared to bigger firms.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased sales of pain management devices. Growth rates can be calculated from historical revenue data.
Future Projections: Analyst projections suggest continued growth in revenue and earnings, driven by market demand for non-opioid pain management solutions. Need current analyst reports for specific numbers.
Recent Initiatives: Recent initiatives include expansion of product line, focus on direct sales model, and marketing efforts to increase brand awareness.
Summary
Zynex Inc. specializes in non-opioid pain management solutions and has a direct sales model. Its growth has been driven by increased sales of its electrotherapy devices. The company faces competition from larger medical device companies and is susceptible to changes in reimbursement policies. Zynex needs to continue to innovate its product line and strategically manage its marketing costs. Its vertically integrated model and focus on the opioid crisis provides significant opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports (FactSet, Bloomberg)
- Company Website
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Accuracy is not guaranteed and is based on publicly available information. Consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zynex Inc
Exchange NASDAQ | Headquaters Englewood, CO, United States | ||
IPO Launch date 2002-12-31 | Founder, President, CEO & Chairman Mr. Thomas Sandgaard | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1000 | Website https://www.zynex.com |
Full time employees 1000 | Website https://www.zynex.com | ||
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.